Uluslararas\u0131 bir ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131na g\u00f6re bilim insanlar\u0131, meme kanseri hastalar\u0131n\u0131n kemoterapiden fayda g\u00f6r\u00fcp g\u00f6rmeyece\u011fini belirleyebilen bir DNA testi geli\u015ftirdi.<\/p>\n
Ara\u015ft\u0131rma, milyonlarca hastan\u0131n kemoterapinin a\u011f\u0131r yan etkilerine maruz kalmadan tedavi edilebilece\u011fini ortaya koydu. Ara\u015ft\u0131rmada yer alan hastalar\u0131n \u00fc\u00e7te ikisinden fazlas\u0131n\u0131n yaln\u0131zca hormon tedavisiyle ba\u015far\u0131l\u0131 \u015fekilde tedavi edilebildi\u011fi belirlendi.<\/p>\n
<\/p>\n
Kemoterapi yorgunluk, mide bulant\u0131s\u0131, sa\u00e7 d\u00f6k\u00fclmesi, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin zay\u0131flamas\u0131 ve do\u011furganl\u0131k sorunlar\u0131 gibi ciddi yan etkilere neden olabiliyor.<\/p>\n
<\/p>\n
University College London (UCL) \u00f6nc\u00fcl\u00fc\u011f\u00fcnde y\u00fcr\u00fct\u00fclen \u00e7al\u0131\u015fmaya \u0130ngiltere, Norve\u00e7, \u0130sve\u00e7, Avustralya, Yeni Zelanda ve Tayland’dan yeni meme kanseri te\u015fhisi konulan 40 ya\u015f \u00fczerindeki 4 binden fazla hasta kat\u0131ld\u0131.<\/p>\n
<\/p>\n
Ara\u015ft\u0131rmac\u0131lar, meme kanserinin b\u00fcy\u00fcmesinde rol oynayan 50 genin faaliyetini \u00f6l\u00e7en “Prosigna” adl\u0131 gen testini kulland\u0131. Test sayesinde hastal\u0131\u011f\u0131n yeniden ortaya \u00e7\u0131kma riski hesapland\u0131. D\u00fc\u015f\u00fck risk puan\u0131 alan ve kat\u0131l\u0131mc\u0131lar\u0131n yakla\u015f\u0131k \u00fc\u00e7te ikisini olu\u015fturan gruba kemoterapi uygulanmad\u0131. Bu grupta be\u015f y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131 y\u00fczde 93,7 olarak kaydedildi.<\/p>\n
<\/p>\n
Tedavisinde kemoterapi kullan\u0131lan hastalarda ise bu oran y\u00fczde 94,9 oldu. Meme kanserinde temel tedavi y\u00f6ntemi genellikle t\u00fcm\u00f6r\u00fcn cerrahi olarak \u00e7\u0131kar\u0131lmas\u0131 olurken, kemoterapi \u00e7o\u011fu zaman hastal\u0131\u011f\u0131n yeniden ortaya \u00e7\u0131kma riskini azaltmak amac\u0131yla ameliyat sonras\u0131nda \u00f6neriliyor. Ayr\u0131ca yak\u0131n lenf d\u00fc\u011f\u00fcmlerine yay\u0131lm\u0131\u015f erken evre meme kanseri hastalar\u0131na da s\u0131kl\u0131kla uygulan\u0131yor.<\/p>\n
<\/p>\n
\u2018\u2019K\u0130\u015e\u0130SELLE\u015eT\u0130R\u0130LM\u0130\u015e TEDAV\u0130YE DO\u011eRU ATILMI\u015e \u00d6NEML\u0130 B\u0130R ADIM”<\/strong><\/p>\n <\/p>\n \u00c7al\u0131\u015fmaya ba\u015fkanl\u0131k eden UCL Kanser Enstit\u00fcs\u00fc Meme Onkolojisi Profes\u00f6r\u00fc Rob Stein, “Ula\u015f\u0131lan sonu\u00e7lar, daha ki\u015fiselle\u015ftirilmi\u015f bir tedaviye do\u011fru at\u0131lm\u0131\u015f \u00f6nemli ve kayda de\u011fer bir ad\u0131m\u0131 temsil ediyor” dedi.<\/p>\n <\/p>\n UCL\u2019ye g\u00f6re \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131 sayesinde \u0130ngiltere\u2019deki kamu sa\u011fl\u0131k sistemi dahilinde y\u0131lda 5 binden fazla hastan\u0131n gereksiz yere kemoterapi almas\u0131n\u0131n \u00f6n\u00fcne ge\u00e7ilebilece\u011fi tahmin ediliyor. UCL\u2019ye g\u00f6re sonu\u00e7lar\u0131n 40 ya\u015f alt\u0131ndakiler i\u00e7in ge\u00e7erli olup olmad\u0131\u011f\u0131 hen\u00fcz bilinmiyor ve bu konuda sonu\u00e7 al\u0131nmas\u0131 i\u00e7in birka\u00e7 y\u0131l daha gerekiyor.<\/p>\n <\/p>\n \u00c7al\u0131\u015fma sonucunda elde edilen sonu\u00e7lar, ABD\u2019nin Chicago kentinde d\u00fczenlenmekte olan d\u00fcnyan\u0131n en b\u00fcy\u00fck kanser konferans\u0131 Amerikan Klinik Onkoloji Derne\u011fi\u2019nin (ASCO) y\u0131ll\u0131k toplant\u0131s\u0131nda sunulacak.<\/p>\n <\/p>\n GEN TEST\u0130<\/strong><\/p>\n <\/p>\n Prosigna gen testi, hastalardan al\u0131nan t\u00fcm\u00f6r dokusundaki belirli 50 genin aktivitesini analiz ederek kanserin molek\u00fcler alt tipini belirliyor ve kemoterapinin gerekli olup olmad\u0131\u011f\u0131n\u0131 belirleme konusunda doktorlara yard\u0131mc\u0131 olmak i\u00e7in hastal\u0131\u011f\u0131n tekrarlama risk puan\u0131n\u0131 hesapl\u0131yor.<\/p>\n <\/p>\n \u00c7al\u0131\u015fma sayesinde, bir\u00e7ok hastan\u0131n kemoterapinin fiziksel ve duygusal y\u00fck\u00fcnden ve ayr\u0131ca muhtemel uzun vadeli yan etkilerinden korunabilece\u011fi \u00f6ng\u00f6r\u00fcl\u00fcyor.<\/p>\n <\/p>\n Meme kanserinde temel tedavi y\u00f6ntemi olarak, t\u00fcm\u00f6rlerin \u00e7\u0131kar\u0131lmas\u0131na y\u00f6nelik cerrahi m\u00fcdahale benimseniyor. Hastal\u0131\u011f\u0131n yeniden ortaya \u00e7\u0131kma riskini azaltmak amac\u0131yla ise \u00e7o\u011fu zaman kemoterapi \u00f6neriliyor.<\/p>\n <\/p>\n Kemoterapi ayr\u0131ca, yak\u0131ndaki lenf d\u00fc\u011f\u00fcmlerine yay\u0131lm\u0131\u015f erken evre meme kanseri hastalar\u0131na da d\u00fczenli bir \u015fekilde uygulan\u0131yor.<\/p>\n <\/p>\n Uzmanlar, a\u011f\u0131r yan etkileri olan kemoterapinin en yayg\u0131n meme kanseri t\u00fcr\u00fcne sahip baz\u0131 hastalar i\u00e7in \u00e7ok az fayda sa\u011flad\u0131\u011f\u0131na i\u015faret ediyor.<\/p>\n \\n\\n<\/p>\n